Fibrin-CAR-T cells therapies to enhance efficacy in glioblastoma treatments

纤维蛋白-CAR-T 细胞疗法可增强胶质母细胞瘤治疗的疗效

基本信息

批准号：
10515887
负责人：
Edikan Ogunnaike
金额：
$ 11.55万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-01 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10515887
关键词：
Address Adverse effects Affect Affinity Agonist Allogenic Angiogenesis Inhibitors Animal Model Animals Area Autologous Avastin Behavior Biocompatible Materials Biological Blood - brain barrier anatomy Blood Vessels Brain Bypass CAR T cell therapy Career Transition Award Cell Therapy Cells Clinical Research Collaborations Combined Modality Therapy Cues Development Plans Dose Drug Delivery Systems Encapsulated Engineering Environment Excision Faculty Failure Fibrin Formulation Future Gel Glioblastoma Goals Growth Heterogeneity Human Hydrogels Immune Immunocompetent Immunosuppression Immunotherapy Inflammatory Institution Interdisciplinary Study Interleukin-15 Knowledge Maintenance Malignant Neoplasms Malignant neoplasm of brain Measures Mentors Modeling Monoclonal Antibodies Nature Oncology Pathogenesis Pharmaceutical Preparations Pharmacy Schools Phenotype Physiological Physiology Play Positioning Attribute Primary Brain Neoplasms Recombinant Cytokines Recurrence Research Research Personnel Residual Tumors Residual state Role Safety Scientist Solubility Surface System T-Lymphocyte TLR7 gene Testing Therapeutic Tissues Toll-like receptors Toxic effect Training Treatment Efficacy Treatment outcome Tumor Burden Tumor-associated macrophages UNC Lineberger Comprehensive Cancer Center Vascular Endothelial Growth Factors angiogenesis antitumor effect base career career development cell mediated immune response chimeric antigen receptor chimeric antigen receptor T cells clinically relevant combat cytokine cytotoxicity design effective therapy engineered T cells exhaustion extracellular fight against human disease immunoengineering improved improved outcome innovation knowledge translation medical schools mouse model nanobiotechnology nanoformulation neoplastic cell next generation novel oral communication prevent programs recruit research study resiquimod skills small molecule spatiotemporal targeted treatment technical writing therapy resistant tumor tumor microenvironment tumor progression tumor-immune system interactions tumorigenesis

项目摘要

Abstract This proposal addresses limitations in the delivery of therapies to treat glioblastoma (GBM), a lethal and hard- to-treat cancer of the brain. We propose regional delivery of chimeric antigen receptor (CAR) T cells for GBM that bypasses the blood-brain barrier. Failure to sustain the delivery to address T cell exhaustion and proliferation while considering the GBM-tumor microenvironment (TME) adversely affects therapeutic antitumor efficacy in both animal models and humans. We develop physiological biomaterial a fibrin-based hydrogel (FBH) encapsulating CAR-T cells (F-CAR-T) that can afford treatment combinations to close these critical gaps and lack of knowledge for translation of the CAR-T cell therapy. The MOSAIC Postdoctoral Career Transition Award proposal demonstrates a resurgence in delivering a cellular therapy approach to treat GBM by understanding biomaterial and immune mechanisms to improve comprehensive tumor targets. Specific Aims are: 1). Increase persistence of CAR-T cells and anti-tumor efficacy by co-delivery of cytokines with F-CAR-T in post-resection GBM model. 2) Determine whether co-delivery of F-CAR-T with TLR 7,8 agonist targeting TAMs can improve outcomes in partial tumor resection GBM model. 3). Determine whether our innovative F-CAR-T can be additive when employed in combination with the approved anti-angiogenic drug, Avastin. This study is relevant to the agency as delivering effective therapies offers fundamental knowledge of relevant approaches to reduce the GBM burden in humans. Dr. Ogunnaike's career goals are to launch a robust and successful research program by receiving a tenure-earning faculty position in an academic institution leading multi-disciplinary research to push the boundaries of biomaterial delivery systems and physiology, from cells to behavior, while mentoring the next generation of cancer researchers in the field of nanobiotechnology and immune engineering. Her career development plans are to gain knowledge and skills in the areas of CAR-T cell therapy, GBM TME, drug delivery and biomaterials. This training is essential for the future studies of advanced delivery and targeted therapy in the candidate's lab. Dr. Ogunnaike's training will include honing management, technical writing, and effective research oral communication skills. Her mentors are Dr. Alexander Kabanov, an expert in drug delivery, and Dr. Gianpietro Dotti, an expert in oncology and CAR-T cell therapy. Her training will be enhanced by collaboration with Dr. Marina Sokolsky, a director of the Translational Nanoformulations Research with expertise in drug delivery and gel carriers; Dr. Shawn Hingtgen, an expert in GBM cell therapy and Dr. Timothy Gershon a clinician scientist both having expertise in GBM animal models. The mentored research will occur within the UNC Eschelman School of Pharmacy (Dr. Kabanov), UNC School of Medicine (Dr. Dotti), and the UNC Lineberger Comprehensive Cancer Center where all mentors and collaborates are affiliated.

抽象的该提案解决了胶质母细胞瘤 (GBM) 治疗方法的局限性，胶质母细胞瘤是一种致命且难治的疾病。治疗脑癌。我们建议针对 GBM 进行嵌合抗原受体 (CAR) T 细胞的区域递送绕过血脑屏障。无法维持递送来解决 T 细胞耗竭和增殖问题同时考虑到 GBM 肿瘤微环境（TME）对治疗抗肿瘤功效产生不利影响动物模型和人类。我们开发生理生物材料基于纤维蛋白的水凝胶（FBH）封装 CAR-T 细胞 (F-CAR-T) 可以提供治疗组合来缩小这些关键差距，缺乏对 CAR-T 细胞疗法转化的了解。 MOSAIC博士后职业转型奖该提案展示了通过理解细胞治疗方法来治疗 GBM 的复兴生物材料和免疫机制，以改善综合肿瘤靶标。具体目标是：1）。增加切除后通过与 F-CAR-T 共同递送细胞因子来实现 CAR-T 细胞的持久性和抗肿瘤功效 GBM模型。 2) 确定 F-CAR-T 与靶向 TAM 的 TLR 7,8 激动剂共同递送是否可以改善部分肿瘤切除 GBM 模型的结果。 3）。确定我们的创新F-CAR-T是否可以叠加与已批准的抗血管生成药物阿瓦斯汀 (Avastin) 联合使用。这项研究与作为提供有效疗法的机构，提供了相关方法的基础知识，以减少人类的 GBM 负担。奥古奈克博士的职业目标是启动一项稳健且成功的研究计划通过在领导多学科研究的学术机构获得终身教职突破生物材料输送系统和生理学的界限，从细胞到行为，同时指导纳米生物技术和免疫工程领域的下一代癌症研究人员。她的事业发展计划旨在获得 CAR-T 细胞治疗、GBM TME、药物输送领域的知识和技能和生物材料。此次培训对于未来先进递送和靶向治疗的研究至关重要候选人的实验室。奥古奈克博士的培训将包括磨练管理、技术写作和有效的研究口头沟通技巧。她的导师是药物输送专家 Alexander Kabanov 博士和 Gianpietro Dotti，肿瘤学和 CAR-T 细胞治疗专家。她的培训将通过合作得到加强与具有药物专业知识的转化纳米制剂研究主任 Marina Sokolsky 博士一起递送和凝胶载体； GBM 细胞治疗专家 Shawn Hingtgen 博士和临床医生 Timothy Gershon 博士科学家都拥有 GBM 动物模型方面的专业知识。指导研究将在北卡罗来纳大学内进行埃舍尔曼药学院（卡巴诺夫博士）、北卡罗来纳大学医学院（多蒂博士）和北卡罗来纳大学莱恩伯格所有导师和合作者都隶属的综合癌症中心。